Literature DB >> 20347266

A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis.

John F M Gleeson1, Mario Alvarez-Jimenez, Sue M Cotton, Alexandra G Parker, Sarah Hetrick.   

Abstract

The prevention of relapse is an important treatment goal in first-episode psychosis. Randomized controlled trials (RCTs) provide the gold standard methodology for evaluating interventions for relapse prevention. Properly designed RCTs which include relapse as a treatment outcome should rigorously operationalize psychotic relapse. The aim of this systematic literature review was to evaluate according to six criteria the operationalization of relapse in RCTs of clinical innovations for the prevention of relapse in first-episode psychosis. Through a systematic literature search of relevant RCTs in first-episode psychosis patients, eight pharmacological and eight non-pharmacological trials, published between 1982 and 2009, were identified. Readmission to a psychiatric hospital was the most common definition of psychotic relapse. Five studies did not measure relapse using any standardized or validated observer-rated instruments. The majority of the studies did not specify a duration criterion for relapse. Only three studies satisfied six criteria for the adequate operationalization of relapse. These results raise concerns regarding the internal and external validity of these research findings. There is an urgent need for a standardized, universally adopted set of criteria for psychotic relapse with appropriate specification of measurement instruments for use in future RCTs. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20347266     DOI: 10.1016/j.schres.2010.02.1073

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  13 in total

Review 1.  Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.

Authors:  M Alvarez-Jimenez; B O'Donoghue; A Thompson; J F Gleeson; S Bendall; C Gonzalez-Blanch; E Killackey; L Wunderink; P D McGorry
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

2.  Improving outcomes of first-episode psychosis: an overview.

Authors:  Paolo Fusar-Poli; Patrick D McGorry; John M Kane
Journal:  World Psychiatry       Date:  2017-10       Impact factor: 49.548

3.  A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up.

Authors:  John F M Gleeson; Sue M Cotton; Mario Alvarez-Jimenez; Darryl Wade; Donna Gee; Kingsley Crisp; Tracey Pearce; Daniela Spiliotacopoulos; Belinda Newman; Patrick D McGorry
Journal:  Schizophr Bull       Date:  2011-11-29       Impact factor: 9.306

4.  Digital smartphone intervention to recognise and manage early warning signs in schizophrenia to prevent relapse: the EMPOWER feasibility cluster RCT.

Authors:  Andrew I Gumley; Simon Bradstreet; John Ainsworth; Stephanie Allan; Mario Alvarez-Jimenez; Maximillian Birchwood; Andrew Briggs; Sandra Bucci; Sue Cotton; Lidia Engel; Paul French; Reeva Lederman; Shôn Lewis; Matthew Machin; Graeme MacLennan; Hamish McLeod; Nicola McMeekin; Cathy Mihalopoulos; Emma Morton; John Norrie; Frank Reilly; Matthias Schwannauer; Swaran P Singh; Suresh Sundram; Andrew Thompson; Chris Williams; Alison Yung; Lorna Aucott; John Farhall; John Gleeson
Journal:  Health Technol Assess       Date:  2022-05       Impact factor: 4.106

5.  Second-generation antipsychotic discontinuation in first episode psychosis: an updated review.

Authors:  Brian J Miller; Chelsea Bodenheimer; Krystle Crittenden
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-08-31       Impact factor: 2.582

6.  Clinical outcomes from the texting for relapse prevention (T4RP) in schizophrenia and schizoaffective disorder study.

Authors:  Bernadette A Cullen; Katrina Rodriguez; William W Eaton; Ramin Mojtabai; Tara Von Mach; Michele L Ybarra
Journal:  Psychiatry Res       Date:  2020-07-29       Impact factor: 3.222

7.  Modeling determinants of medication attitudes and poor adherence in early nonaffective psychosis: implications for intervention.

Authors:  Richard J Drake; Merete Nordentoft; Gillian Haddock; Celso Arango; W Wolfgang Fleischhacker; Birte Glenthøj; Marion Leboyer; Stefan Leucht; Markus Leweke; Phillip McGuire; Andreas Meyer-Lindenberg; Dan Rujescu; Iris E Sommer; René S Kahn; Shon W Lewis
Journal:  Schizophr Bull       Date:  2015-03-05       Impact factor: 9.306

8.  High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China.

Authors:  Jingbo Xiao; Weifeng Mi; Lingzhi Li; Ying Shi; Hongyan Zhang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-05-08       Impact factor: 2.570

Review 9.  Maintenance antipsychotic treatment versus discontinuation strategies following remission from first episode psychosis: systematic review.

Authors:  Andrew Thompson; Catherine Winsper; Steven Marwaha; Jon Haynes; Mario Alvarez-Jimenez; Sarah Hetrick; Alba Realpe; Laura Vail; Sarah Dawson; Sarah A Sullivan
Journal:  BJPsych Open       Date:  2018-06-29

10.  Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.

Authors:  Jun Ishigooka; Kazuyuki Nakagome; Tetsuro Ohmori; Nakao Iwata
Journal:  BMC Psychiatry       Date:  2013-10-03       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.